Valuation: NEOVACS

Market Cap 4.09T 4.67T 3.8T 3.49T 6.57T 5L 6.67T 45.22T 17.7T 2L 17.52T 17.14T 8L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.21Cr -3L -22.23L -9L -1.08Cr -9L -8L -3.74Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
3 years 16,000
Extreme 16000
10,00,000
5 years 16,000
Extreme 16000
10,00,000
10 years 16,000
Extreme 16000
10,00,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-20.00%-.--% - - 1L
+1.45%-5.63%-4.87%+11.80% 4.61TCr
+4.41%+5.91%+405.65%+631.57% 3.89TCr
+0.75%+0.76%+8.48%+63.82% 3.56TCr
+4.99%-0.71%+7.60%-8.40% 3.31TCr
-0.87%-3.19%-1.27%+29.16% 2.64TCr
+1.05%-2.81% - - 1.66TCr
+16.82%+15.20%+41.67%+150.94% 1.51TCr
-4.93%-3.57%+5.90%+9.64% 1.41TCr
+3.52%+2.95%+4.24%-27.87% 1.28TCr
Average +0.75%-2.25%+58.43%+107.58% 2.65TCr
Weighted average by Cap. +2.78%-2.60%+75.86%+134.81%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.87Cr 9L 58.99L 23.09L 2.87Cr 22.85L 22.36L 9.93Cr 4L 5L 4L 4L 7L 4.78Cr 7L 47.99L 18.78L 2.34Cr 18.59L 18.19L 8.08Cr
Net income -87.43L -99.79L -81.17L -74.59L -1.41Cr -96Cr -1.43Cr -9.67Cr -3.78Cr -47Cr -3.75Cr -3.67Cr -162.76Cr -3.29Cr -3.76Cr -3.06Cr -2.81Cr -5.29Cr -362.48Cr -5.37Cr -36Cr -14Cr -177.37Cr -14Cr -14Cr -612.72Cr
Net Debt -2L -3L -2L -2L -4L -2.6Cr -4L -26.16L -10.24L -1.27Cr -10.13L -10L -4.4Cr -2L -2L -2L -2L -3L -2.26Cr -3L -22.68L -9L -1.11Cr -9L -9L -3.82Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16